← Back to Search

Other

aumolertinib for Liver Damage

Phase 1
Waitlist Available
Research Sponsored by EQRx, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose
Awards & highlights
No Placebo-Only Group

Summary

This trial involves people with severe liver problems taking a single tablet of EQ143. The study will monitor the drug and its breakdown product in their blood, check how they bind to proteins, and ensure it is safe.

Eligible Conditions
  • Liver Damage

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose
This trial's timeline: 3 weeks for screening, Varies for treatment, and predose and 1, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 120, 168, and 192 hours post dose for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
PK Parameter: AUC0-t of EQ143
PK Parameter: AUC0-t of metabolite, HAS719
PK Parameter: AUCinf of EQ143
+4 more
Secondary study objectives
Number of Participants with Adverse Event

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: AumolertinibExperimental Treatment1 Intervention
single dose oral 55mg of aumolertinib
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
aumolertinib
2021
Completed Phase 1
~60

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

EQRx, Inc.Lead Sponsor
3 Previous Clinical Trials
145 Total Patients Enrolled
EQRx International, Inc.Lead Sponsor
3 Previous Clinical Trials
8 Total Patients Enrolled
~3 spots leftby Dec 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top